Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Differential impact of cognitive computing augmented by real world evidence on novice and expert oncologists.

McNamara DM, Goldberg SL, Latts L, Atieh Graham DM, Waintraub SE, Norden AD, Landstrom C, Pecora AL, Hervey J, Schultz EV, Wang CK, Jungbluth N, Francis PM, Snowdon JL.

Cancer Med. 2019 Nov;8(15):6578-6584. doi: 10.1002/cam4.2548. Epub 2019 Sep 11.

2.

An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer.

Stewart M, Norden AD, Dreyer N, Henk HJ, Abernethy AP, Chrischilles E, Kushi L, Mansfield AS, Khozin S, Sharon E, Arunajadai S, Carnahan R, Christian JB, Miksad RA, Sakoda LC, Torres AZ, Valice E, Allen J.

JCO Clin Cancer Inform. 2019 Jul;3:1-15. doi: 10.1200/CCI.18.00155.

3.

A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States.

Norden AD, Korytowsky B, You M, Kim Le T, Dastani H, Bobiak S, Singh P.

J Manag Care Spec Pharm. 2019 Apr;25(4):428-436. doi: 10.18553/jmcp.2019.25.4.428.

4.

Development of a Precise, Clinically Relevant, Digital Classification Schema for Cancer.

Pecora AL, Norden AD, Hervey J, Schultz EV, Gallucci TL, Rushforth E, Goldberg SL.

JCO Clin Cancer Inform. 2018 Dec;2:1-10. doi: 10.1200/CCI.18.00006.

5.

Realizing the Promise of Cognitive Computing in Cancer Care: Ushering in a New Era.

Norden AD, Dankwa-Mullan I, Urman A, Suarez F, Rhee K.

JCO Clin Cancer Inform. 2018 Dec;2:1-6. doi: 10.1200/CCI.17.00049. Review. No abstract available.

6.

A Patient-Reported Outcome Instrument to Assess Symptom Burden and Predict Survival in Patients with Advanced Cancer: Flipping the Paradigm to Improve Timing of Palliative and End-of-Life Discussions and Reduce Unwanted Health Care Costs.

Goldberg SL, Paramanathan D, Khoury R, Patel S, Jagun D, Arunajadai S, DeVincenzo V, Benito RP, Gruman B, Kaur S, Paddock S, Norden AD, Schultz EV, Hervey J, Jordan T, Goy A, Pecora AL.

Oncologist. 2019 Jan;24(1):76-85. doi: 10.1634/theoncologist.2018-0238. Epub 2018 Sep 28.

7.

Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma.

Lee EQ, Duda DG, Muzikansky A, Gerstner ER, Kuhn JG, Reardon DA, Nayak L, Norden AD, Doherty L, LaFrankie D, Stefanik J, Vardam T, Smith KH, McCluskey C, Gaffey S, Batchelor TT, Jain RK, Wen PY.

Clin Cancer Res. 2018 Oct 1;24(19):4643-4649. doi: 10.1158/1078-0432.CCR-18-1025. Epub 2018 Jun 25.

8.

Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board.

Somashekhar SP, Sepúlveda MJ, Puglielli S, Norden AD, Shortliffe EH, Rohit Kumar C, Rauthan A, Arun Kumar N, Patil P, Rhee K, Ramya Y.

Ann Oncol. 2018 Feb 1;29(2):418-423. doi: 10.1093/annonc/mdx781.

9.

A Descriptive Analysis of End-of-Life Conversations With Long-Term Glioblastoma Survivors.

Miranda SP, Bernacki RE, Paladino JM, Norden AD, Kavanagh JE, Palmor MC, Block SD.

Am J Hosp Palliat Care. 2018 May;35(5):804-811. doi: 10.1177/1049909117738996. Epub 2017 Nov 9.

PMID:
29121789
10.

Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone.

Arvold ND, Shi DD, Aizer AA, Norden AD, Reardon DA, Lee EQ, Nayak L, Dunn IF, Golby AJ, Johnson MD, Claus EB, Chiocca EA, Ligon KL, Wen PY, Alexander BM.

J Neurooncol. 2017 Dec;135(3):581-591. doi: 10.1007/s11060-017-2611-9. Epub 2017 Oct 3.

PMID:
28975467
11.

Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients.

Jiang S, Hill K, Patel D, Waldeck AR, Botteman M, Aly A, Norden AD.

J Med Econ. 2017 Dec;20(12):1237-1243. doi: 10.1080/13696998.2017.1364258. Epub 2017 Aug 16.

PMID:
28777020
12.

Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).

Rost NS, Giugliano RP, Ruff CT, Murphy SA, Crompton AE, Norden AD, Silverman S, Singhal AB, Nicolau JC, SomaRaju B, Mercuri MF, Antman EM, Braunwald E; ENGAGE AF-TIMI 48 Investigators.

Stroke. 2016 Aug;47(8):2075-82. doi: 10.1161/STROKEAHA.116.013540. Epub 2016 Jul 7.

PMID:
27387994
13.

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy.

Lee EQ, Muzikansky A, Drappatz J, Kesari S, Wong ET, Fadul CE, Reardon DA, Norden AD, Nayak L, Rinne ML, Alexander BM, Arvold ND, Doherty L, Stefanik J, LaFrankie D, Ruland SF, Pulverenti J, Smith KH, Gaffey SC, Hammond S, Wen PY.

Neuro Oncol. 2016 Jun;18(6):849-54. doi: 10.1093/neuonc/now007. Epub 2016 Feb 21.

14.

Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.

Castillo JJ, D'Sa S, Lunn MP, Minnema MC, Tedeschi A, Lansigan F, Palomba ML, Varettoni M, Garcia-Sanz R, Nayak L, Lee EQ, Rinne ML, Norden AD, Ghobrial IM, Treon SP.

Br J Haematol. 2016 Mar;172(5):709-15. doi: 10.1111/bjh.13883. Epub 2015 Dec 21.

15.

Author response.

Wen PY, Norden AD.

Neurology. 2015 Sep 22;85(12):1090. No abstract available.

PMID:
26645061
16.

Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy.

Armstrong TS, Grant R, Gilbert MR, Lee JW, Norden AD.

Neuro Oncol. 2016 Jun;18(6):779-89. doi: 10.1093/neuonc/nov269. Epub 2015 Nov 2. Review.

17.

A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma.

Aizer AA, Abedalthagafi M, Bi WL, Horvath MC, Arvold ND, Al-Mefty O, Lee EQ, Nayak L, Rinne ML, Norden AD, Reardon DA, Wen PY, Ligon KL, Ligon AH, Beroukhim R, Dunn IF, Santagata S, Alexander BM.

Neuro Oncol. 2016 Feb;18(2):269-74. doi: 10.1093/neuonc/nov177. Epub 2015 Aug 30.

18.

Extent of resection and overall survival for patients with atypical and malignant meningioma.

Aizer AA, Bi WL, Kandola MS, Lee EQ, Nayak L, Rinne ML, Norden AD, Beroukhim R, Reardon DA, Wen PY, Al-Mefty O, Arvold ND, Dunn IF, Alexander BM.

Cancer. 2015 Dec 15;121(24):4376-81. doi: 10.1002/cncr.29639. Epub 2015 Aug 26.

19.

Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation.

Rahman R, Catalano PJ, Reardon DA, Norden AD, Wen PY, Lee EQ, Nayak L, Beroukhim R, Dunn IF, Golby AJ, Johnson MD, Chiocca EA, Claus EB, Alexander BM, Arvold ND.

J Neurooncol. 2015 Aug;124(1):137-46. doi: 10.1007/s11060-015-1820-3. Epub 2015 Jun 2.

PMID:
26033544
20.

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.

Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY.

Clin Cancer Res. 2015 Aug 15;21(16):3610-8. doi: 10.1158/1078-0432.CCR-14-3220. Epub 2015 Apr 24.

21.

Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma.

Ramkissoon SH, Bi WL, Schumacher SE, Ramkissoon LA, Haidar S, Knoff D, Dubuc A, Brown L, Burns M, Cryan JB, Abedalthagafi M, Kang YJ, Schultz N, Reardon DA, Lee EQ, Rinne ML, Norden AD, Nayak L, Ruland S, Doherty LM, LaFrankie DC, Horvath M, Aizer AA, Russo A, Arvold ND, Claus EB, Al-Mefty O, Johnson MD, Golby AJ, Dunn IF, Chiocca EA, Trippa L, Santagata S, Folkerth RD, Kantoff P, Rollins BJ, Lindeman NI, Wen PY, Ligon AH, Beroukhim R, Alexander BM, Ligon KL.

Neuro Oncol. 2015 Oct;17(10):1344-55. doi: 10.1093/neuonc/nov015. Epub 2015 Mar 9.

22.

Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.

Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, Gaffey SC, Wrigley B, Ligon KL, Raizer JJ, Wen PY.

Neuro Oncol. 2015 Jun;17(6):862-7. doi: 10.1093/neuonc/nou350. Epub 2015 Jan 7. Erratum in: Neuro Oncol. 2015 Dec;17(12):1650.

23.

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.

Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ, Doherty L, Lafrankie D, Gaffey SC, Gerard M, Smith KH, McCluskey C, Phuphanich S, Wen PY.

Neurology. 2015 Jan 20;84(3):280-6. doi: 10.1212/WNL.0000000000001153. Epub 2014 Dec 19.

24.

Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.

Chheda MG, Wen PY, Hochberg FH, Chi AS, Drappatz J, Eichler AF, Yang D, Beroukhim R, Norden AD, Gerstner ER, Betensky RA, Batchelor TT.

J Neurooncol. 2015 Feb;121(3):627-34. doi: 10.1007/s11060-014-1680-2. Epub 2014 Dec 13.

25.

Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.

Taylor JW, Dietrich J, Gerstner ER, Norden AD, Rinne ML, Cahill DP, Stemmer-Rachamimov A, Wen PY, Betensky RA, Giorgio DH, Snodgrass K, Randall AE, Batchelor TT, Chi AS.

J Neurooncol. 2015 Feb;121(3):557-63. doi: 10.1007/s11060-014-1667-z. Epub 2014 Nov 20.

26.

Welcoming the era of quality improvement in neuro-oncology.

Norden AD.

J Oncol Pract. 2014 Nov;10(6):371-2. doi: 10.1200/JOP.2014.001206. No abstract available.

PMID:
25398956
27.

Antiangiogenic therapies for glioblastoma.

Arrillaga-Romany I, Norden AD.

CNS Oncol. 2014;3(5):349-58. doi: 10.2217/cns.14.31. Review.

28.

Medical management of brain tumors and the sequelae of treatment.

Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA, Wen PY.

Neuro Oncol. 2015 Apr;17(4):488-504. doi: 10.1093/neuonc/nou304. Epub 2014 Oct 30. Review.

29.

Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.

Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Doherty LM, LaFrankie DC, Pulverenti JR, Rifenburg JA, Ruland SF, Smith KH, Gaffey SC, McCluskey C, Ligon KL, Reardon DA, Wen PY.

J Neurooncol. 2015 Jan;121(2):297-302. doi: 10.1007/s11060-014-1631-y. Epub 2014 Oct 22.

PMID:
25338318
30.

Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.

Rahman R, Hempfling K, Norden AD, Reardon DA, Nayak L, Rinne ML, Beroukhim R, Doherty L, Ruland S, Rai A, Rifenburg J, LaFrankie D, Alexander BM, Huang RY, Wen PY, Lee EQ.

Neuro Oncol. 2014 Nov;16(11):1523-9. doi: 10.1093/neuonc/nou118. Epub 2014 Jun 23.

31.

Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.

Rahman R, Hamdan A, Zweifler R, Jiang H, Norden AD, Reardon DA, Mukundan S, Wen PY, Huang RY.

J Neurooncol. 2014 Aug;119(1):149-58. doi: 10.1007/s11060-014-1464-8. Epub 2014 May 8.

PMID:
24805151
32.

Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: a gene expression imaging study.

Lee JW, Norden AD, Ligon KL, Golby AJ, Beroukhim R, Quackenbush J, Wells W, Oelschlager K, Maetzold D, Wen PY.

Epilepsy Res. 2014 Jul;108(5):843-52. doi: 10.1016/j.eplepsyres.2014.02.021. Epub 2014 Mar 12.

33.

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.

Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL.

Neuro Oncol. 2014 Apr;16(4):567-78. doi: 10.1093/neuonc/not247. Epub 2014 Jan 26.

34.

Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival.

Chen C, Huang R, MacLean A, Muzikansky A, Mukundan S, Wen PY, Norden AD.

J Neurooncol. 2013 Nov;115(2):267-76. doi: 10.1007/s11060-013-1225-0. Epub 2013 Aug 22.

PMID:
23974656
35.

Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma.

Zhang JP, Lee EQ, Nayak L, Doherty L, Kesari S, Muzikansky A, Norden AD, Chen H, Wen PY, Drappatz J.

J Neurooncol. 2013 Oct;115(1):71-7. doi: 10.1007/s11060-013-1196-1. Epub 2013 Jul 5.

PMID:
23828279
36.

Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.

Huang RY, Rahman R, Hamdan A, Kane C, Chen C, Norden AD, Reardon DA, Mukundun S, Wen PY.

Cancer. 2013 Oct 1;119(19):3479-88. doi: 10.1002/cncr.28210. Epub 2013 Jul 2.

37.

Update on bevacizumab and other angiogenesis inhibitors for brain cancer.

Rinne ML, Lee EQ, Nayak L, Norden AD, Beroukhim R, Wen PY, Reardon DA.

Expert Opin Emerg Drugs. 2013 Jun;18(2):137-53. doi: 10.1517/14728214.2013.794784. Epub 2013 May 14. Review.

PMID:
23668489
38.

Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.

Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY.

Neuro Oncol. 2013 Jul;15(7):930-5. doi: 10.1093/neuonc/not040. Epub 2013 Apr 3.

39.

DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues.

Craig JM, Vena N, Ramkissoon S, Idbaih A, Fouse SD, Ozek M, Sav A, Hill DA, Margraf LR, Eberhart CG, Kieran MW, Norden AD, Wen PY, Loda M, Santagata S, Ligon KL, Ligon AH.

PLoS One. 2012;7(6):e38881. doi: 10.1371/journal.pone.0038881. Epub 2012 Jun 15.

40.

Atypical and anaplastic meningiomas treated with bevacizumab.

Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ.

J Neurooncol. 2012 Aug;109(1):187-93. doi: 10.1007/s11060-012-0886-4. Epub 2012 Apr 29.

PMID:
22544653
41.

Current concepts in brain tumor imaging.

Norden AD, Pope WB, Chang SM.

Am Soc Clin Oncol Educ Book. 2012:119-24. doi: 10.14694/EdBook_AM.2012.32.119.

PMID:
24451720
42.

Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.

Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R, Gerard M, Schiff D, Chi AS, Batchelor TT, Doherty LM, Ciampa AS, Lafrankie DC, Ruland S, Snodgrass SM, Raizer JJ, Wen PY.

J Neurooncol. 2012 Mar;107(1):133-8. doi: 10.1007/s11060-011-0717-z. Epub 2011 Oct 8.

PMID:
21984064
43.

Discontinuing bevacizumab in patients with glioblastoma: an ethical analysis.

Kesselheim JC, Norden AD, Wen PY, Joffe S.

Oncologist. 2011;16(10):1435-9. doi: 10.1634/theoncologist.2011-0047. Epub 2011 Sep 23.

44.

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.

Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE 2nd, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS.

J Neurooncol. 2012 Jan;106(2):409-15. doi: 10.1007/s11060-011-0687-1. Epub 2011 Sep 22.

45.

Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients.

Norden AD, Bartolomeo J, Tanaka S, Drappatz J, Ciampa AS, Doherty LM, Lafrankie DC, Ruland S, Quant EC, Beroukhim R, Wen PY.

J Neurooncol. 2012 Jan;106(1):121-5. doi: 10.1007/s11060-011-0642-1. Epub 2011 Jun 26.

PMID:
21706358
46.

Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure.

Lu-Emerson C, Norden AD, Drappatz J, Quant EC, Beroukhim R, Ciampa AS, Doherty LM, Lafrankie DC, Ruland S, Wen PY.

J Neurooncol. 2011 Aug;104(1):287-91. doi: 10.1007/s11060-010-0489-x. Epub 2010 Dec 14.

PMID:
21153679
47.

Longitudinal MRI evidence for decreased survival among periventricular glioblastoma.

Young GS, Macklin EA, Setayesh K, Lawson JD, Wen PY, Norden AD, Drappatz J, Kesari S.

J Neurooncol. 2011 Aug;104(1):261-9. doi: 10.1007/s11060-010-0477-1. Epub 2010 Dec 5.

48.

Recurrent high-grade glioma.

Quant EC, Drappatz J, Wen PY, Norden AD.

Curr Treat Options Neurol. 2010 Jul;12(4):321-33. doi: 10.1007/s11940-010-0078-5.

PMID:
20842591
49.

Medical therapies for meningiomas.

Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD.

J Neurooncol. 2010 Sep;99(3):365-78. doi: 10.1007/s11060-010-0349-8. Epub 2010 Sep 4. Review.

PMID:
20820875
50.

Survival among patients with primary central nervous system lymphoma, 1973-2004.

Norden AD, Drappatz J, Wen PY, Claus EB.

J Neurooncol. 2011 Feb;101(3):487-93. doi: 10.1007/s11060-010-0269-7. Epub 2010 Jun 17.

PMID:
20556477

Supplemental Content

Loading ...
Support Center